Home
Conditions
Hematologic Neoplasms

Clinical trial condition

Hematologic Neoplasms

Explore clinical trials studying Hematologic Neoplasms. Study availability and eligibility vary by location and protocol.

1,027 public trials 268 recruiting studies

Refine in advanced search Browse all conditions

Hematologic Neoplasms trial results

Active, Not Recruiting

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

NCT04565665

Conditions: COVID-19, COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, +19 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

NCT05102656

Conditions: COVID-19, COVID-19 Infection, Coronaviridae Infections, +17 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies

NCT07251348

Conditions: Hematologic Diseases, Hematologic Neoplasms, Hematological Cancer, +3 more
Locations: Seydişehir Kamil Akkanat Sağlik Bilimleri Fakültesi Konya, Seydi̇şehi̇r, Turkey (Türkiye)

View Trial Details

Active, Not Recruiting

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses

NCT04960787

Conditions: Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +9 more
Locations: Fairbanks Memorial Hospital Fairbanks, Alaska, United States

Mercy Hospital Fort Smith Fort Smith, Arkansas, United States

Kaiser Permanente-Deer Valley Medical Center Antioch, California, United States

Epic Care-Dublin Dublin, California, United States

View all 266 locations

View Trial Details

Active, Not Recruiting

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +20 more
Locations: Banner MD Anderson Cancer Center Gilbert, Arizona, United States

UCLA Ronald Reagan Medical Center Los Angeles, California, United States

Mayo Clinic Jacksonville, Florida, United States

Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois, United States

View all 43 locations

View Trial Details

Active, Not Recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

NCT04439110

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

NCT04439266

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

NCT04439279

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

NCT04439331

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

NCT05256537

Conditions: Hematologic Diseases, Hematologic Neoplasms, Hemic and Lymphatic Diseases, +2 more
Locations: Cedars-Sinai Medical Center Los Angeles, California, United States

View Trial Details

Hematologic Neoplasms

Hematologic Neoplasms trial results

Related conditions